AUXL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
|Louis Moore Bacon 150,000 sh (New)||John Paulson 4,000,000 sh (unchged)||Jim Simons Sold Out|
Paul Tudor Jones Sold Out
|Mario Gabelli 10,900 sh (New)||John Paulson 4,000,000 sh (unchged)||Louis Moore Bacon 100,000 sh (-33.33%)|
|Jim Simons 468,040 sh (New)|
Jeremy Grantham 1,281,312 sh (New)
Mario Gabelli 35,885 sh (+229.22%)
|Louis Moore Bacon Sold Out|
John Paulson Sold Out
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
|Short Percentage of Float||29.16%|
|52-Week Range $||17.10 - 37.93|
|EPS without NRI($)||-0.05||2.60||3.50|
|Industry:||Drug Manufacturers » Drug Manufacturers - Specialty & Generic|
|Compare:||SHSE:600521, SZSE:000999, HKSE:00867, NAS:HZNP, NAS:AKRX, NYSE:CTLT » details|
|Traded in other countries:||FEJ.Germany,|
|Auxilium Pharmaceuticals, Inc., incorporated in the state of Delaware in July 1999. The Company is a specialty biopharmaceutical company which develops and markets products for specialist audiences. The Company now have a portfolio of 12 approved products, including one product with two indications. Among other products in the U.S., Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy ("TRT") product, STENDRA (avanafil), an oral erectile dysfunction ("ED") therapy, Edex (alprostadil for injection), an injectable treatment for ED, Osbon ErecAid, the leading vacuum device for aiding ED, XIAFLEX (collagenase clostridium histolyticum or "CCH") for the treatment of Peyronie's disease ("PD" or "Peyronie's") and XIAFLEX for the treatment of Dupuytren's contracture ("DC" or "Dupuytren's"). We also have programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite, Striant, a buccal TRT, XIAFLEX for the treatment of PD in men with a palpable plaque and a curvature deformity of thirty degrees or greater at the start of therapy which was launched in the U.S. in January 2014 and is the first and only FDA-approved non-surgical treatment for PD. Approximately 75% of the Company's product shipments are to only three wholesalers: Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation. The Company faces competition from competitors in North America, Europe and elsewhere from pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products.|
|Endo International Posts Upbeat Q1 Results May 13 2015|
|Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015|
|Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015|
|John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014|
|Auxilium Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011|
|Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010|
|Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010|
|Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010|
|Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009|
|Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 16 2009|